{
    "root": "2f11f18f-b8ba-968d-e063-6394a90a972c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Carvedilol",
    "value": "20250226",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CROSPOVIDONE (12 MPA.S AT 5%)",
            "code": "40UAA97IT9"
        },
        {
            "name": "CARVEDILOL",
            "code": "0K47UL67F2"
        }
    ],
    "indications": "carvedilol tablets alpha/beta-adrenergic blocking agent indicated treatment : mild severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction clinically stable patients ( 1.2 ) hypertension ( 1.3 )",
    "contraindications": "take food . individualize monitor up-titration . ( 2 ) heart failure : start 3.125 mg twice daily increase 6.25 , 12.5 , 25 mg twice daily intervals least 2 weeks . maintain lower doses higher doses tolerated . ( 2.1 ) left ventricular dysfunction following myocardial infarction : start 6.25 mg twice daily increase 12.5 mg 25 mg twice daily intervals 3 10 days . lower starting dose slower titration may used . ( 2.2 ) hypertension : start 6.25 mg twice daily increase needed blood pressure control 12.5 mg 25 mg twice daily intervals 1 2 weeks . ( 2.3 )",
    "warningsAndPrecautions": "carvedilol tablets usp , 25 mg white off-white , round , biconvex , beveled edge , film-coated tablets debossed 'zc42 ' one side plain side supplied follows : ndc : 70518-1826-00 ndc : 70518-1826-01 ndc : 70518-1826-02 packaging : 30 1 blister pack packaging : 180 1 bottle plastic packaging : 90 1 bottle plastic store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . protect moisture . dispense tight , light-resistant container . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "bronchial asthma related bronchospastic conditions . ( 4 ) second- third-degree av block . ( 4 ) sick sinus syndrome . ( 4 ) severe bradycardia ( unless permanent pacemaker place ) . ( 4 ) patients cardiogenic shock decompensated heart failure requiring iv inotropic therapy . ( 4 ) severe hepatic impairment . ( 2.4 , 4 ) history serious hypersensitivity reaction ( e.g . , stevens-johnson syndrome , anaphylactic reaction , angioedema ) component medication medications containing carvedilol . ( 4 )",
    "indications_original": "Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 )",
    "contraindications_original": "Take with food. Individualize dosage and monitor during up-titration. ( 2 ) Heart failure: Start at 3.125 mg twice daily and increase to 6.25, 12.5, and then 25 mg twice daily over intervals of at least 2 weeks. Maintain lower doses if higher doses are not tolerated. ( 2.1 ) Left ventricular dysfunction following myocardial infarction: Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily after intervals of 3 to 10 days. A lower starting dose or slower titration may be used.( 2.2 ) Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg and then 25 mg twice daily over intervals of 1 to 2 weeks.( 2.3 )",
    "warningsAndPrecautions_original": "Carvedilol Tablets USP, 25 mg are white to off-white, round, biconvex, beveled edge, film-coated tablets debossed with 'ZC42' on one side and plain on other side and are supplied as follows:\n                  NDC: 70518-1826-00\n                  NDC: 70518-1826-01\n                  NDC: 70518-1826-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 180 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Protect from moisture. Dispense in a tight, light-resistant container.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Bronchial asthma or related bronchospastic conditions. ( 4 ) Second- or third-degree AV block. ( 4 ) Sick sinus syndrome. ( 4 ) Severe bradycardia (unless permanent pacemaker in place). ( 4 ) Patients in cardiogenic shock or decompensated heart failure requiring the use of IV inotropic therapy. ( 4 ) Severe hepatic impairment. ( 2.4 , 4 ) History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol. ( 4 )"
}